Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
A prospective, single-center, double-blind, randomized, placebo-controlled crossover study of Ursodeoxycholic acid (UDCA) in 17 clinically stable male patients with Chronic heart failure (CHF) (New York Heart Association functional class II/III, left ventricular ejection fraction <45%). Patients received in random order 500 mg UDCA twice daily for 4 weeks and placebo for another 4 weeks.
Primary outcome measures:
Peripheral blood flow as assessed by venous occlusion plethysmography
The authors concluded that Ursodeoxycholic acid (UDCA) is well tolerated in patients with Chronic heart failure (CHF). UDCA improves peripheral blood flow and is associated with improved markers of liv…